Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
Save to Existing Project
Save to a New Project
Compound for Treatment of Psoriasis
Health Technologies at Strathclyde United Kingdom flag United Kingdom
Abstract ID:
A proprietary compound that can be applied topically to reduce excessive proliferation of skin cells...
Email me a copy of this message


Psoriasis is a skin disease characterised by inflammation and scaly lesions of the skin affecting 2-3% of the population in Europe and North America. Several different therapies are currently being used to treat psoriasis, but they all have the possibility of serious side effects. Additionally, they are expensive to produce and lack efficacy in some patients.


Researchers at the University of Strathclyde have isolated a novel compound for the treatment of psoriasis from a plant extract of Calendula officinalis (marigold). The compound has anti-proliferative effects against normal skin cells growing in tissue culture and has cleared initial regulatory toxicology testing. The compound can be applied locally to affected areas of the skin, thereby minimising the chances of systemic side effects.

Key Benefits

Topical application

Regulatory toxicology data available

Derived from clinically proven natural product

Active compound can be synthesised chemically

Novel mechanism of action

Economical manufacture

Markets and Applications

This compound could be applied topically to affected areas of the skin for the treatment of psoriasis.

Type of Business Relationship Sought

Contact is welcomed from parties interested in this project.

Last Updated Feb 2014
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE